SCHEMBL21294451

SCHEMBL21294451

O=C(O)CCOCCOCCNc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O

nearest known ligand 0.66

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 4/20 0.66
▸ MAP1LC3B Q9GZQ8 7/20 0.59
▸ CRBN Q96SW2 6/20 0.56
▸ IKZF3 Q9UKT9 2/20 0.52
▸ IKZF1 Q13422 2/20 0.52
▸ BRD4 O60885 2/20 0.52
▸ TNF P01375 1/20 0.52
▸ IL1B P01584 1/20 0.52
▸ DDB1 Q16531 1/20 0.52
▸ CSNK1A1 P48729 1/20 0.50
▸ HDAC3 O15379 1/20 0.49
▸ HDAC1 Q13547 1/20 0.49
▸ AXL P30530 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30996464 1.00 STAT3 (0.66) STAT3MAP1LC3BCRBNIKZF3IKZF1
SCHEMBL21332800 1.00 STAT3 (0.66) STAT3MAP1LC3BCRBNIKZF3IKZF1
SCHEMBL21303980 1.00 STAT3 (0.66) STAT3MAP1LC3BCRBNIKZF3IKZF1
SCHEMBL21304422 0.99 STAT3 (0.65) STAT3MAP1LC3BCRBNIKZF3IKZF1
SCHEMBL28970883 0.96 STAT3 (0.65) STAT3MAP1LC3BCRBNIKZF3IKZF1
SCHEMBL30437920 0.96 STAT3 (0.65) STAT3MAP1LC3BCRBNIKZF3IKZF1
SCHEMBL22773798 0.94 STAT3 (0.67) STAT3MAP1LC3BCRBNIKZF3IKZF1
SCHEMBL20933049 0.94 STAT3 (0.67) STAT3MAP1LC3BCRBNIKZF3IKZF1
SCHEMBL22788954 0.94 STAT3 (0.67) STAT3MAP1LC3BCRBNIKZF3IKZF1
SCHEMBL22789078 0.94 STAT3 (0.67) STAT3MAP1LC3BCRBNIKZF3IKZF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12318452-B2 Degraders of WEE1 kinase DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-06-03 — — US disclosed
WO-2024145315-A1 TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) NORTHWESTERN UNIVERSITY (US) 2024-07-04 — — WO disclosed
WO-2024145315-A1 TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) NORTHWESTERN UNIVERSITY (US) 2024-07-04 — — WO disclosed
US-11771697-B2 Small molecule degraders of polybromo-1 (PBRM1) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-03 — — US disclosed
US-11771697-B2 Small molecule degraders of polybromo-1 (PBRM1) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-03 — — US disclosed
US-11771697-B2 Small molecule degraders of polybromo-1 (PBRM1) DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-03 — — US disclosed
US-20220047709-A1 DEGRADERS OF WEE1 KINASE DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 — — US disclosed
US-20220047709-A1 DEGRADERS OF WEE1 KINASE DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 — — US disclosed
EP-3787747-A1 SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) Dana-Farber Cancer Institute, Inc. (US) 2021-03-10 — — EP disclosed
US-20210038599-A1 SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-02-11 — — US disclosed
US-20210038599-A1 SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-02-11 — — US disclosed
US-10689366-B2 Compounds for MALT1 degredation CORNELL UNIVERSITY (US) 2020-06-23 — — US disclosed
US-10689366-B2 Compounds for MALT1 degredation CORNELL UNIVERSITY (US) 2020-06-23 — — US disclosed
WO-2020069105-A1 DEGRADERS OF WEE1 KINASE DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-04-02 — — WO disclosed
EP-3535254-A1 COMPOUNDS FOR MALT1 DEGRADATION Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") (US) 2019-09-11 — — EP disclosed
US-20190263785-A1 COMPOUNDS FOR MALT1 DEGRADATION CORNELL UNIVERSITY (US) 2019-08-29 — — US disclosed
US-20190263785-A1 COMPOUNDS FOR MALT1 DEGRADATION CORNELL UNIVERSITY (US) 2019-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689366-B2 Compounds for MALT1 degredation CRBN, NFKB2, NFKB1 STAT3 1185/4885MAP1LC3B 557/4885CRBN 1/4885
US-11771697-B2 Small molecule degraders of polybromo-1 (PBRM1) PBRM1, SMARCC1, SMARCC2 STAT3 1439/4885MAP1LC3B 346/4885CRBN 65/4885
US-20190263785-A1 COMPOUNDS FOR MALT1 DEGRADATION CRBN, NFKB2, NFKB1 STAT3 1020/4885MAP1LC3B 393/4885CRBN 1/4885
US-20220047709-A1 DEGRADERS OF WEE1 KINASE WEE1, WEE2, PPME1 STAT3 2042/4885MAP1LC3B 2748/4885CRBN 553/4885
US-12318452-B2 Degraders of WEE1 kinase WEE1, WEE2, PPME1 STAT3 2042/4885MAP1LC3B 2748/4885CRBN 553/4885
US-20210038599-A1 SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) PBRM1, SMARCC1, SMARCC2 STAT3 1439/4885MAP1LC3B 346/4885CRBN 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback